Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.50 |
| ▸ | AKT3 | Q9Y243 | 16/20 | 0.50 |
| ▸ | AKT2 | P31751 | 11/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | PRKCB | P05771 | 4/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.47 |
| ▸ | RPS6KA1 | Q15418 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24085528 | 0.84 | AKT1 (0.51) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| SCHEMBL22307580 | 0.84 | AKT1 (0.50) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| SCHEMBL22308403 | 0.84 | AKT1 (0.50) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| SCHEMBL22288501 | 0.82 | AKT1 (0.58) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| SCHEMBL24085522 | 0.78 | AKT1 (0.50) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| SCHEMBL24085581 | 0.78 | AKT3 (0.56) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| SCHEMBL22308404 | 0.78 | AKT3 (0.56) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL30933072 | 0.76 | AKT1 (0.51) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL30933088 | 0.76 | AKT1 (0.51) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| SCHEMBL28608776 | 0.75 | AKT3 (0.51) | AKT1AKT3AKT2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021228223-A1 | DEUTERATED AKT KINASE INHIBITOR | 南京正大天晴制药有限公司 | 2021-11-18 | — | — | WO | disclosed |